Eli Lilly and Company (LLY)
| Market Cap | 659.09B |
| Revenue (ttm) | 53.26B |
| Net Income (ttm) | 13.80B |
| Shares Out | 897.74M |
| EPS (ttm) | 15.29 |
| PE Ratio | 48.01 |
| Forward PE | 26.48 |
| Dividend | $6.00 (0.82%) |
| Ex-Dividend Date | Aug 15, 2025 |
| Volume | 4,326,154 |
| Open | 736.96 |
| Previous Close | 736.03 |
| Day's Range | 731.55 - 746.59 |
| 52-Week Range | 623.78 - 972.48 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 978.56 (+33.29%) |
| Earnings Date | Aug 7, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price target is $978.56, which is an increase of 33.29% from the latest price.
News
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
Eli Lilly has temporarily paused shipments of its weight-loss drug Mounjaro in the UK, ahead of a new price hike for the treatment set to come into effect starting next month.
The bear case on Eli Lilly has played out, says only firm to have called it a sell
The bear case for Eli Lilly has now played out following the reaction to the drugmaker's oral obesity drug trial, an analyst said Wednesday in upgrading the stock.
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy
Treatment with Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone In the seven-year ...
Citi's Geoff Meacham on Eli Lilly's stock climbing as weight loss pill clears latest trial
Geoff Meacham, Citi Research Managing Director, joins 'Fast Money' to talk competition in the weight loss drug space as Eli Lilly's weight loss pill clears its latest trial.
S&P 500 Gains and Losses Today: Eli Lilly Stock Soars as Weight-Loss Pill Shows Promise; Beverage Makers Face Pressure
Major U.S. equities indexes ticked higher as investors looked past concerns about President Donald Trump's effort to remove Federal Reserve Governor Lisa Cook and ahead to Wednesday's Nvidia earnings ...
Healthy Returns: Eli Lilly's chief scientific officer breaks down the latest obesity pill data
Eli Lilly's Daniel Skovronsky talks the latest orforglipron trial, while UnitedHealth Group CEO Stephen Hemsley is moving quickly on a strategic turnaround.
Eli Lilly Stock Jumps On Weight-Loss Pill Trial
Eli Lilly and Co. LLY stock has experienced significant volatility over the past six months, primarily driven by reactions to developments in its weight-loss drug portfolio.
Top Stock Movers Now: Eli Lilly, EchoStar, Constellation Brands, and More
U.S. equities were little changed at midday on limited market-driving corporate earnings news and economic data. The Dow Jones Industrial Average, S&P 500, and Nasdaq all moved by small amounts.
Eli Lilly's Obesity Pill Moves Closer to Approval
Eli Lilly & Co.'s experimental obesity pill helped patients lose 9.6% of their body weight in a trial that moves the company one step closer to a potential approval. Damian Garde has more on "Bloomber...
Guggenheim Partner's Seamus Fernandez: Oral weight loss pill 'meaningful step up' for Eli Lilly
Seamus Fernandez, Guggenheim Partners biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest data on Eli Lilly's obesity pill.
LLY Weight Loss Drug Momentum, AT&T's (T) $23B EchoStar Licenses, ULTA Price Target Hikes
AT&T (T) secured a deal worth $23 billion with EchoStar (SATS) to buy spectrum licenses from the company. Eli Lilly (LLY) tacked on billions of dollars in market share after its experimental weight lo...
Eli Lilly Stock Rises as Firm Plans to Ask for Weight-Loss Pill Approval
Eli Lilly (LLY) shares gained more than 4% soon after the opening bell Tuesday as results from a new study moved the drugmaker closer to applying for approval of its experimental weight-loss pill.
Cramer's Stop Trading: Eli Lilly
Jim Cramer breaks down why he's keeping an eye on shares of Eli Lilly.
Lilly obesity-pill trial results find a warmer reception on Wall Street this time around
Pharmaceutical giant Eli Lilly said it will now move “with urgency” toward getting regulatory approval for orforglipron.
Eli Lilly's weight loss pill will likely be the market-leading product, says BofA's Tim Anderson
Tim Anderson, BofA Securities senior pharma analyst, joins 'Squawk Box' to discuss news of Eli Lilly's weight loss pill orforglipron clearing its latest trial, what it means for the drug going forward...
Eli Lilly stock jumps in pre-market trading: what's driving the surge?
Eli Lilly & Co's experimental obesity pill orforglipron helped patients lose 9.6% of their body weight in a late-stage trial, moving the drug a step closer to potential approval.
Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals
Eli Lilly said a third late-stage study of its experimental anti-obesity pill hit its key goals, paving the way for the drugmaker to begin regulatory submissions.
Lilly pill cuts body weight by 10.5% in patients with type 2 diabetes
Eli Lilly said on Tuesday its experimental GLP-1 pill helped overweight adults with type 2 diabetes shed 10.5% of body weight in a late-stage trial, after recent data from another study of the drug in...
Eli Lilly Says New Pill Results in 10.5% Weight-Loss for Diabetes Patients
Lilly said it's moving “with urgency toward global regulatory submissions to potentially meet the needs of patients who are waiting.”
Eli Lilly's weight loss pill orforglipron clears its latest trial, paving way for approval
Eli Lilly on Tuesday said its daily obesity pill succeeded in another late-stage trial, helping patients with obesity and Type 2 diabetes lose weight and lower their blood sugar levels. The company no...
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
In ATTAIN-2, orforglipron met the primary and all key secondary endpoints, with compelling efficacy results and a safety profile consistent with injectable GLP-1 medicines Participants with obesity or...
Lilly to participate in Morgan Stanley 23rd Annual Global Healthcare Conference
INDIANAPOLIS , Aug. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on Sept. 8, 2025. Jacob Van Naarden, execu...
Healthcare stocks: are they well-positioned to weather Trump tariffs?
The Trump administration's sweeping tariffs have sent ripples through the healthcare sector in 2025. Last week, the US government locked in pharmaceutical tariffs on the EU at 15%.
Immuneering Announces Clinical Supply Agreement with Lilly to Evaluate Atebimetinib in Combination with Olomorasib
- Immuneering to evaluate atebimetinib in combination with olomorasib in planned Phase 2 trial in patients with advanced non-small cell lung cancer – CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -...
Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite data that underwhelmed investors
Some analysts say Eli Lilly's daily obesity pill, if approved, could still be a viable competitor in the weight loss drug market despite late-stage trial data that disappointed investors. In the trial...